Acil Servise Lamotrijinin Yan Etkisi ile Başvuru; Stevens Johnson Sendromu

Amaç: Stevens Johnson Sendromu ve Toksik Epidermal Nekroliz (SJS/TEN), hayatı tehdit edebilen, etiyolojisinde çeşitli faktörler olmakla birlikte genellikle ilaçlara karşı gelişen mukokutanöz cilt reaksiyonudur. Bu vaka sunumu ile anti-epileptik ilaç kullanımına bağlı gelişen SJS kısaca gözden geçirilecektir. Olgu: 20 yaşında kadın hasta jeneralize tonik klonik nöbet ile acil serviste görüldü. Alınan ayrıntılı anamnez ve laboratuvar bulguları ile hastaya lamotirijin tedavisi başlandı. Tedavide doz titre edilirken SJS gelişen hastada tedavi kesilerek yeni anti-epileptik ilaç başlandı. Sonuç: SJS/TEN farklı şiddette olan aynı hastalık spektrumudur. Cilt dekolmanı alanının yüzdesine göre sınıflanırlar. SJS/TEN’in patogenezi hala belirsizdir ve optimal tedavi seçenekleri tartışmalıdır. Etiyolojide sıkça ilaçlar sorumlu tutulmaktadır.

Side Effect of Lamotrigine in the Emergency Department; Stevens-Johnson Syndrome

Aim: Stevens Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN) is a life-threatening mucocutaneous skin reaction that usually develops against drugs, although there are various factors in its etiology. In this case report, SJS due to antiepileptic drug use will be briefly reviewed. Case:20-year-old female patient was seen in the emergency department with a generalized tonic-clonic seizure. With the detailed anamnesis and laboratory findings obtained, the patient was started lamothyrigine therapy. While the dose was titrated in the treatment, treatment was stopped in the patient who developed SJS, and a new antiepileptic drug was started. Conclusion: SJS/TEN is the same disease spectrum with different severity. They are classified according to the percentage of skin detachment area. The pathogenesis of SJS/TEN is still unclear and optimal treatment options are still controversial.

PDF

___

1. Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Research. 2020;9:612.
2. Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Care Med 2011;39:1521-32.
3. Sunaga Y, Kurosawa M, Ochiai H, et al. The nationwide epidemiological survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan, 2016-2018. J Dermatol Sci. 2020;100:175-82.
4. S. Alvestad, S. Lydersen, E. Brodtkorb, Rash from antiepileptic drugs: influence by gender, age, and learning disability, Epilepsia. 2007; 48:1360–65.
5. Fukasawa T, Takahashi H, Takahashi K, et al. Risk of StevensJohnson syndrome and toxic epidermal necrolysis associated with anticonvulsants in a Japanese population: Matched casecontrol and cohort studies. Allergol Int. 2021;70(3):335-42.
6. Alpsoy E, Dicle Ö, Karakaş AA. Steven-Johnson Syndrome (SJS) and toxic epidermal necrolysis. Turkderm. 2010;44(4):180–6.
7. Stefan H, Feuerstein TJ. Novel anticonvulsant drugs. Pharmacol Ther. 2007;113(1):165–83.
8. Özcan H, Cenk H, Cumurcu B Lamotrijin ve valproik asidin birlikte kullanımı sonucunda gelişen toksik epidermal nekroliz olgusu. Türkderm. 2015; 49: 169-72.
9. Ghislain PD, Roujeau JC: Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity syndrome. Dermatol Online J. 2002;8:5.
10. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008; 128:35-44.